These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15789920)

  • 41. [A special case of thyroid associated ophthalmopathy in the course of Graves-Basedow disease].
    Bałdys-Waligórska A; Kuśnierz-Cabala B; Huszno B
    Endokrynol Pol; 2006; 57(5):536-40. PubMed ID: 17133319
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dramatic response to cholestyramine in a patient with Graves' disease resistant to conventional therapy.
    Sebastián-Ochoa A; Quesada-Charneco M; Fernández-García D; Reyes-García R; Rozas-Moreno P; Escobar-Jiménez F
    Thyroid; 2008 Oct; 18(10):1115-7. PubMed ID: 18816181
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Jod-Basedow effect due to prolonged use of lugol solution-case report.
    Leuştean L; Preda C; Ungureanu MC; Dănilă R; Mogoş V; Stefănescu C; Vulpoi C
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(4):1013-7. PubMed ID: 25581962
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Evaluation of a logistic regression model in predicting the prognosis of Graves' disease treated by antithyroid drugs].
    Wei S; Pan X; Liang Z; Xu S; Cheng Y; Li J
    Hua Xi Yi Ke Da Xue Xue Bao; 1991 Sep; 22(3):314-7. PubMed ID: 1748419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pancytopenia in untreated patients with Graves' disease.
    Lima CS; Zantut Wittmann DE; Castro V; Tambascia MA; Lorand-Metze I; Saad ST; Costa FF
    Thyroid; 2006 Apr; 16(4):403-9. PubMed ID: 16646688
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Graves' disease presenting with severe cholestasis.
    Regelmann MO; Miloh T; Arnon R; Morotti R; Kerkar N; Rapaport R
    Thyroid; 2012 Apr; 22(4):437-9. PubMed ID: 22458973
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The effects of intensive DMPA regimen in the treatment of Graves' ophthalmopathy].
    Wei S; Tong N; Luo Q; Tian H; Yu Y; Liu Y
    Hua Xi Yi Ke Da Xue Xue Bao; 1996 Sep; 27(3):306-9. PubMed ID: 9389069
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical evolution of a cohort of patients with Graves-Basedow disease treated with metimazole].
    De Luis DA; Arconada A; Aller R; Cuéllar LA; Terroba MC; Martín Gil J
    Med Clin (Barc); 2002 Jun; 118(20):777-8. PubMed ID: 12049693
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of high and low doses of methimazole in patients with Graves' thyrotoxicosis.
    Benker G; Reinwein D; Creutzig H; Hirche H; Alexander WD; McCruden D; Galvan G; Kahály G; Beyer J; Lazarus JH
    Acta Endocrinol Suppl (Copenh); 1987; 281():312-7. PubMed ID: 3303792
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Graves' disease and liver abnormalities: antithyroid drugs are not the only factors involved!].
    Zabulon A; Gelu-Simeon M; Bélia L; Chingan V; Duflo S; Vélayoudom-Céphise FL
    Presse Med; 2015 Jan; 44(1):110-2. PubMed ID: 25530575
    [No Abstract]   [Full Text] [Related]  

  • 51. Antithyroid drug regimen for treating Graves' hyperthyroidism.
    Abraham P; Avenell A; McGeoch SC; Clark LF; Bevan JS
    Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD003420. PubMed ID: 20091544
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigational drugs in early stage clinical trials for thyrotoxicosis with hyperthyroidism.
    Gómez-Sáez JM
    Expert Opin Investig Drugs; 2018 Nov; 27(11):831-837. PubMed ID: 30354697
    [TBL] [Abstract][Full Text] [Related]  

  • 53. B cell depletion in Graves' disease: the right answer to the wrong question?
    Smith TJ
    J Clin Endocrinol Metab; 2007 May; 92(5):1620-2. PubMed ID: 17483377
    [No Abstract]   [Full Text] [Related]  

  • 54. Reversible, severe mitral regurgitation in thyrotoxic Graves' disease.
    Fekri K; Michel CM; Tamilia M
    BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33541945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effect of Tripterygium glycosides on thyroid function and auto-antibody in patients with Graves disease].
    Tang L; Liang ZQ; Su K
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2003 Apr; 23(4):294-5. PubMed ID: 12764916
    [No Abstract]   [Full Text] [Related]  

  • 56. [Clinical observation on xiehuo yangyin powder in treating 30 initial stage of toxic and diffuse goiter patients].
    Li XM; Cao YF; Yang J
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2003 Nov; 23(11):829-31. PubMed ID: 14666764
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recurrence of thyrotoxicosis after attack of allergic rhinitis in patients with Graves' disease.
    Hidaka Y; Amino N; Iwatani Y; Itoh E; Matsunaga M; Tamaki H
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1667-70. PubMed ID: 8263157
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relapse of Graves' disease in a patient with pheochromocytoma.
    Abe M; Mori K; Nagai K; Ito S
    Endocr J; 2003 Dec; 50(6):767-70. PubMed ID: 14709850
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A systematic review of drug therapy for Graves' hyperthyroidism.
    Abraham P; Avenell A; Park CM; Watson WA; Bevan JS
    Eur J Endocrinol; 2005 Oct; 153(4):489-98. PubMed ID: 16189168
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hypoglycemia due to insulin binding antibodies in a patient with insulin-treated type 2 diabetes and Graves' disease.
    Wang X; Xu XL; Zhao XL; Ma XW; Yu H; Gong H; Zhang SR; Chen FL
    Endocrine; 2013 Feb; 43(1):236-7. PubMed ID: 22886314
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.